FY2024 EPS Estimates for Neurogene Reduced by William Blair

Neurogene Inc. (NASDAQ:NGNE) – William Blair dropped their FY2024 earnings estimates for Neurogene in a research report issued to clients and investors on Tuesday, November 19th. William Blair analyst S. Corwin now expects that the company will post earnings of ($4.33) per share for the year, down from their prior estimate of ($4.31). William Blair currently has a “Outperform” rating on the stock. The consensus estimate for Neurogene’s current full-year earnings is ($4.45) per share. William Blair also issued estimates for Neurogene’s Q4 2024 earnings at ($1.04) EPS, Q1 2025 earnings at ($1.08) EPS, Q2 2025 earnings at ($1.05) EPS, Q3 2025 earnings at ($1.09) EPS, Q4 2025 earnings at ($1.11) EPS and FY2025 earnings at ($4.32) EPS.

NGNE has been the topic of a number of other research reports. Robert W. Baird raised their price target on Neurogene from $54.00 to $72.00 and gave the stock an “outperform” rating in a research report on Tuesday, November 12th. Stifel Nicolaus raised their target price on shares of Neurogene from $44.00 to $60.00 and gave the company a “buy” rating in a report on Tuesday, November 12th. BMO Capital Markets dropped their target price on shares of Neurogene from $60.00 to $45.00 and set an “outperform” rating for the company in a research report on Wednesday. HC Wainwright reiterated a “buy” rating and set a $55.00 price target on shares of Neurogene in a research report on Tuesday. Finally, Leerink Partners boosted their price objective on shares of Neurogene from $45.00 to $72.00 and gave the company an “outperform” rating in a research report on Tuesday, November 12th. Eight equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Buy” and a consensus target price of $60.83.

Neurogene Stock Performance

Neurogene stock opened at $20.30 on Thursday. The stock’s fifty day moving average price is $44.97 and its two-hundred day moving average price is $39.53. Neurogene has a one year low of $12.49 and a one year high of $74.49.

Hedge Funds Weigh In On Neurogene

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. FMR LLC grew its stake in shares of Neurogene by 912.4% during the third quarter. FMR LLC now owns 731,801 shares of the company’s stock worth $30,706,000 after buying an additional 659,515 shares during the last quarter. Vanguard Group Inc. increased its holdings in Neurogene by 906.5% in the 1st quarter. Vanguard Group Inc. now owns 507,483 shares of the company’s stock worth $25,831,000 after purchasing an additional 457,062 shares in the last quarter. Jennison Associates LLC acquired a new position in Neurogene in the 3rd quarter worth about $3,300,000. Integral Health Asset Management LLC bought a new position in Neurogene in the second quarter valued at about $2,547,000. Finally, RTW Investments LP boosted its stake in shares of Neurogene by 6.0% during the third quarter. RTW Investments LP now owns 1,135,256 shares of the company’s stock valued at $47,635,000 after purchasing an additional 64,691 shares in the last quarter. Institutional investors own 52.37% of the company’s stock.

Neurogene Company Profile

Neurogene Inc, a biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 which is packaged in an adeno-associated virus 9 that is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease.